War on Cancer – 05-2010
A Big Boost for Hyperthermia
The January 20, 2010, issue of the Journal of the National Cancer Institute (JNCI) contained a highly positive, three-page news article on the use of hyperthermia (heat therapy) in cancer. The pretext for the article was a positive clinical trial with local hyperthermia in sarcoma reported at the European Society of Medical Oncology meeting in Berlin last fall. This randomized trial showed that patients given chemotherapy plus hyperthermia had a median disease-free survival of 32 months, whereas those who got chemotherapy alone had a survival of 18 months. Although this difference was statistically significant, there was no significant difference in overall survival. The most frequent side effect of hyperthermia (104 to 109 ºF) was “mild to moderate discomfort” (in 45%), whereas the most serious side effect was a severe burn seen in one patient (0.6%).
The trial’s lead investigator, Rolf Issels, MD, PhD, said that the treatment provided a “new standard treatment option.” However, Issels continued, “The implications of these findings are more far-reaching. This is also the first clear evidence that targeted heat therapy adds to chemotherapy.”
In the US, as well, long-time investigators of hyperthermia hailed the findings. “We are on a verge, I think, of a major new adjuvant cancer therapy that will not replace chemotherapy or radiation but will make them work a lot better,” said Elizabeth A. Repasky, PhD, of Roswell Park Cancer Institute (Buffalo, NY) and president of the Society for Thermal Medicine, which promotes research and clinical use of hyperthermia.
Others expressed skepticism about the actual impact of the sarcoma trial. “I have been in the field 20 years, and I see how much benefit patients have, but institutions are not willing to use it,” said Zeljko Vujaskovic, MD, PhD, a radiation oncologist at Duke University Medical Center. Duke, a leading center of hyperthermia research, is the only US institution that participated in the Issels study.
The JNCI author, Renee Twombley, tries to provide some explanations for the neglect of hyperthermia, particularly in the US. These are basically (1) the technical demands of operating the hyperthermia equipment; (2) the current FDA requirement that probes be inserted into tumors in order to accurate measure temperatures; and (3) and the historically low insurance reimbursement rates.
The lack of what Twombley calls “abundant evidence” that the treatment can affect overall survival also plays a role. This explanation raises the question of why other cancer treatments, such as the drug Avastin (bevacizumab) for breast cancer, have not been shown to affect overall survival, yet are approved by the FDA and by the oncology community as a whole. (In fact, as Twombley later shows, there is a positive trial showing overall life extension for hyperthermia.)
“The dilemma we face,” said researcher Peter Corry, PhD, “relates to premature clinical trials run in the early ’80s that showed no benefit.”
Another problem is that there is presently only one manufacturer of hyperthermia equipment in the US, BSD Medical Corp. of Salt Lake City. Advocates point out that there is a greater choice of innovative machinery available in Europe, as well as new thermal nanotechnology that may lead to breakthroughs in the field. (Nonetheless, BSD’s stock soared 37% upon publication of the JNCI article.)
The JNCI article detailed the “checkered history” of hyperthermia with radiation or chemotherapy. In the 1970s and 1980s, preliminary reports of benefit supported the use of mild temperatures to increase the effectiveness of radiation. Various devices using microwave, ultrasound, or radio frequencies were built to treat tumors. These received premarket approval from the FDA, and in 1984 hyperthermia was approved for insurance reimbursement.
The Failed RTOG Trial
Then came some clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) that failed to show clinical benefit. In one large randomized, controlled study, there was little difference in response between patients who received radiation and patients who were treated with hyperthermia and radiation for localized tumors. This was a body blow to hyperthermia. Amazingly, however, glaring issues of quality control could probably account for the negative result, according to Corry. For instance, in the aforementioned trial, different centers used different equipment, and 75% of the tumors treated were so large that heating the entire mass to an average of 43 ºC (109.4 ºF), the standard at the time, was not possible.
Also, says the JNCI, almost one-third of the tumors that were treated were never tested for an internal temperature, so it was not certain that the tumors in question were ever actually heated! Problems with equipment and technique also emerged in the course of the trial. The machinery had difficulty maintaining a uniform tumor temperature; and, in any case, researchers did not know what was an effective dose. Mark Dewhirst, DVD, PhD, of Duke University has reviewed the study and said that the design was clearly inadequate.
But the negative study had its effect. The general enthusiasm for hyperthermia (once called oncology’s fourth modality) soon dwindled, as did the research funds and insurance reimbursement. Companies stopped making the devices, which in any case were probably ineffective. In fact, many of today’s researchers blame the FDA for approving these devices for use in general practice, which in their eyes severely tainted hyperthermia. Most critically, radiation oncologists moved on to other emerging technologies, such as three-dimensional conformal radiotherapy. Few people wanted to associate themselves with what was perceived as a dead or dying field.
Once again, Germany and its neighbors led the way. While Americans largely deserted the field, the Germans learned from the failed trials and continued to improve their equipment and their study designs. Last year the Dutch Deep Hyperthermia Trial found that radiation plus hyperthermia improved overall survival compared with radiation alone (51% vs. 27% at 3 years) for patients with locally advanced cervical cancer. It was a hugely important finding – demonstrating rigorously that hyperthermia does indeed significantly increase (in fact, nearly double) survival in a major form of cancer.
Jacoba van der Zee, MD, PhD, is a Dutch leader in the field. She uses hyperthermia to treat cervical, breast, and head and neck cancers, as well as melanoma. They also believe that it will work in rectal and vaginal cancers. Van der Zee reflects the widespread European belief that hyperthermia should be used more often than it is now.
“With all the efforts to find new treatments that are more tumor selective and less toxic, it is astonishing that an existing treatment that is relatively tumor selective, has a low toxicity, and that in clinical studies has been shown to result in considerable benefit receives so little attention,” she said.
American immunologist Repasky went even further, raising the possibility of using hot baths and saunas to raise temperatures in conjunction with standard therapies. (One of the inspirations for hyperthermia was the popular “Schlenz bath” of the 1930s and 1940s.)
Repasky has evidence from animal studies that mild heat improves natural immunity to cancer as well as immune function. Perhaps, she told JNCI, fever-range heat or a hot tub may provide some benefit to cancer patients about to receive chemotherapy or radiation.
“Now wouldn’t offering patients a sauna be a nice, patient-friendly adjuvant therapy?” she asked. “We have a lot to be excited about in this field.”
Asparagus and Cancer
I recently was told by one of my phone consultees that he was taking a purée of asparagus as a treatment for his prostate cancer. For 35 years, I have been hearing about the allegedly curative properties of asparagus. There is indeed a single scientific study from China indicating that an asparagus extract can kill some cancer cells in the test tube (Liu 2009). But the Internet story of an alleged asparagus cure both predates that, and also goes way beyond it in its claims. It has all the hallmarks of an urban myth.
The “asparagus cure” apparently originated with one Richard R. Vensal, DDS. There are thousands of references to this Dr. Vensal on the Internet, but no explanation of who he was or how he arrived at his astonishing idea. No Richard Vensal is the author of any PubMed-listed scientific articles or any books in the gigantic National Library of Medicine catalog. I do remember some articles on the topic of the asparagus cure in Prevention and other health magazines in the 1970s. But, if I remember correctly, these were unsupported by scientific studies.
The Guinea Pig Connection
Ironically, there is indeed a connection between asparagus and cancer, but it not in the manner that most people believe. The real asparagus–cancer story began with an observation by the research pathologist John G. Kidd (1909–1991) at New York Hospital-Cornell Medical Center in 1953. Kidd discovered that the blood serum of healthy guinea pigs killed leukemia and a few other types of cancer in mice. A few years later, Dr. John D. Broome of Texas figured out why. Guinea pigs have in their blood an enzyme called L-asparaginase, which destroys the amino acid L-asparagine. Normal cells generally manufacture their own L-asparagine, but leukemia cells are often unable to do so. They have to “steal” their supply from normal cells.
So the idea arose of using L-asparaginase as a cancer treatment, and it turned out to occasionally be dramatically effective. In 1967 Time magazine reported on the complete remission of one of the first patients to receive the drug:
Nine-year-old Frank Hayes Jr. had been in the last stages of acute leukemia when Dr. Joseph M. Hill began giving him injections of the bacterial extract, L-asparaginase. Within a month, the boy’s grotesquely swollen glands had shrunk, and analysis of his blood cells showed no active cancer.
“Cancer: secret from the guinea pigs.” Time, April 14, 1967
Subsequent treatments were rarely as dramatic as this, but the drug was found helpful. As a result, to this day, L-asparaginase (now called Elspar) is part of the standard regimen for acute lymphoblastic leukemia (ALL) as well as some other rare tumors. The basic idea is to destroy as much of the circulating L-asparagine as possible, in order to starve the leukemic cells.
Most cancer cells, however, resemble normal cells in their ability to synthesize L-asparagine, and so L-asparaginase has little activity on them. But for people with ALL and certain rare cancers, eating a great many asparagus, with their abundant supply of L-asparagine, would seem to be a bad idea, especially if they are currently on a regimen containing Elspar. It would be counterproductive.
That said, I don’t mean to denigrate that possibility that asparagus (like so many other plants) might some day be shown to contain helpful constituents. Last year, researchers in Nanjing, China, reported the presence of a compound called Asparanin A from standard asparagus. It is “an active cytotoxic component,” they said. Asparanin A arrests cell growth and also induces apoptosis (the most common form of programmed cell deaths) in human liver cancer cells. Asparanin A “shows promise as a preventive and/or therapeutic agent” against human liver cancer (Liu 2009). But this is a far cry from the claims of an asparagus cure that one finds circulating in viral fashion on the Internet these days.
References
Broome JD. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114.
———. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exptl Med. 1963;118:99.
———. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med. 1963;118:121.
Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med. 1953;98:565.
———. Regression of transplanted lymphomas induced in viva by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression; tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. Y. Exptl. Meal. 1953;98:583.
Liu W, Huang X, Qi Q, et al. Asparanin A induces G(2)/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochem Biophys Res Commun. 2009;381:700–705.
Old LJ, Boyse EA, Campbell HA, Daria GM. Leukaemia inhibiting properties and r.-asparaginase activity of sera from certain South American rodents. Nature. 1963;198:801.
Twombley R. International study of hyperthermia spurs hope in U.S. advocates. J Natl Canc Inst. 2010;102(2):79–81.
Ralph W. Moss, PhD, is the author of 12 books on cancer-related topics. The former science writer at Memorial Sloan-Kettering Cancer Center, for 35 years Moss has investigated the validity of many cancer treatments. He currently directs the Moss Reports, a library of reports for patients on over 200 different cancer diagnoses.









0 Comments